top of page

CROI 2023: Dr. Dieffenbach Shares Research Highlights on Long-Acting HIV Prevention and Treatment ..


CROI 2023: Dr. Dieffenbach Shares Research Highlights on Long-Acting HIV Prevention and Treatment, COVID, and a Cure Update

Dr. Dieffenbach highlighted a real-world demonstration study by Dr. Monica Gandhi of the University of California San Francisco that found that long-acting antiretroviral treatment (LA-ART) given every four to eight weeks and delivered with comprehensive support services suppressed HIV in people who were previously not virologically suppressed and who experienced housing insecurity, mental illnesses, and substance use disorders. Notably, the study participants included individuals who were on ART but were not virally suppressed and others who were not on ART, which would generally make them ineligible to start LA-ART. Dr. Gandhi reported that all of those participants achieved viral suppression on LA-ART, concluding that LA-ART can be effective for individuals facing challenges to adhering to daily oral ART, particularly when combined with wrap-around services to address challenges such as unstable housing, mental health issues, and/or substance use disorders. Read more about this study.



Comments

Rated 0 out of 5 stars.
No ratings yet

Add a rating
HIV and Mental Health Platform
www.eatg.org

Contact us

Interoffices | Avenue des Arts 56-4c, 1000 Brussels, Belgium

General Inquiries: +32 2 626 96 40

Be the first to know! Join the mailing list.

Thanks for subscribing!

The HIV & Mental Health project has been developed by the EATG, and was made possible through a grant from Gilead Sciences Europe Ltd, Merck Sharp and Dohme, and ViiV Healthcare Europe Ltd. . EATG acknowledges that the sponsors had no control or input into the structure or the content of the initiative.

by EATG

bottom of page